These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35232398)

  • 1. Structural insights into the non-inhibitory mechanism of the anti-EGFR EgB4 nanobody.
    Zeronian MR; Doulkeridou S; van Bergen En Henegouwen PMP; Janssen BJC
    BMC Mol Cell Biol; 2022 Mar; 23(1):12. PubMed ID: 35232398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural evaluation of EGFR inhibition mechanisms for nanobodies/VHH domains.
    Schmitz KR; Bagchi A; Roovers RC; van Bergen en Henegouwen PM; Ferguson KM
    Structure; 2013 Jul; 21(7):1214-24. PubMed ID: 23791944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paper Title "Hu7CG2: A Novel Humanized Anti-Epidermal Growth Factor Receptor (EGFR) Biparatopic Nanobody".
    Sharifi J; Khirehgesh MR; Akbari B; Soleymani B; Mansouri K
    Mol Biotechnol; 2021 Jun; 63(6):525-533. PubMed ID: 33772436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.
    Roovers RC; Vosjan MJ; Laeremans T; el Khoulati R; de Bruin RC; Ferguson KM; Verkleij AJ; van Dongen GA; van Bergen en Henegouwen PM
    Int J Cancer; 2011 Oct; 129(8):2013-24. PubMed ID: 21520037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conformational nanobodies reveal tethered epidermal growth factor receptor involved in EGFR/ErbB2 predimers.
    Nevoltris D; Lombard B; Dupuis E; Mathis G; Chames P; Baty D
    ACS Nano; 2015 Feb; 9(2):1388-99. PubMed ID: 25603171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorescently tagged nanobodies and NanoBRET to study ligand-binding and agonist-induced conformational changes of full-length EGFR expressed in living cells.
    Comez D; Glenn J; Anbuhl SM; Heukers R; Smit MJ; Hill SJ; Kilpatrick LE
    Front Immunol; 2022; 13():1006718. PubMed ID: 36505413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural insights into the role and targeting of EGFRvIII.
    Bagchi A; Stayrook SE; Xenaki KT; Starbird CA; Doulkeridou S; El Khoulati R; Roovers RC; Schmitz KR; van Bergen En Henegouwen PMP; Ferguson KM
    Structure; 2024 Jun; ():. PubMed ID: 38908376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular and functional insight into anti-EGFR nanobody: Theranostic implications for malignancies.
    Tripathy RK; Pande AH
    Life Sci; 2024 May; 345():122593. PubMed ID: 38554946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural basis of V
    King MT; Huh I; Shenai A; Brooks TM; Brooks CL
    J Biol Chem; 2018 Aug; 293(35):13626-13635. PubMed ID: 29976754
    [No Abstract]   [Full Text] [Related]  

  • 10. Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies.
    Tintelnot J; Baum N; Schultheiß C; Braig F; Trentmann M; Finter J; Fumey W; Bannas P; Fehse B; Riecken K; Schuetze K; Bokemeyer C; Rösner T; Valerius T; Peipp M; Koch-Nolte F; Binder M
    Mol Cancer Ther; 2019 Apr; 18(4):823-833. PubMed ID: 30824613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A camelid nanobody against EGFR was easily obtained through refolding of inclusion body expressed in Escherichia coli.
    Xu L; Song X; Jia L
    Biotechnol Appl Biochem; 2017 Nov; 64(6):895-901. PubMed ID: 28853185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of EGFR by a novel multivalent nanobody-liposome platform.
    Oliveira S; Schiffelers RM; van der Veeken J; van der Meel R; Vongpromek R; van Bergen En Henegouwen PM; Storm G; Roovers RC
    J Control Release; 2010 Jul; 145(2):165-75. PubMed ID: 20362020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation and characterization of humanized nanobodies targeting the dimer interface of epidermal growth factor receptor (EGFR).
    Zhu H; Zhao L; Li Z; Wen B; Qiu C; Liu M; Xu Z; Hu S; Li H
    Protein Expr Purif; 2019 May; 157():57-62. PubMed ID: 30735705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human IgG antibodies recognizing distinct extracellular domains of EGF receptor exhibit different degrees of growth inhibitory effects on human A431 cancer cells.
    Chang C; Takayanagi A; Yoshida T; Shimizu N
    Exp Cell Res; 2013 May; 319(8):1146-55. PubMed ID: 23499740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanobody binding to a conserved epitope promotes norovirus particle disassembly.
    Koromyslova AD; Hansman GS
    J Virol; 2015 Mar; 89(5):2718-30. PubMed ID: 25520510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a novel anti-EGFR nanobody by phage display and its distinct paratope and epitope via homology modeling and molecular docking.
    Xi X; Sun W; Su H; Zhang X; Sun F
    Mol Immunol; 2020 Dec; 128():165-174. PubMed ID: 33130376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanistic analysis of allosteric and non-allosteric effects arising from nanobody binding to two epitopes of the dihydrofolate reductase of Escherichia coli.
    Oyen D; Wechselberger R; Srinivasan V; Steyaert J; Barlow JN
    Biochim Biophys Acta; 2013 Oct; 1834(10):2147-57. PubMed ID: 23911607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient growth inhibition of EGFR over-expressing tumor cells by an anti-EGFR nanobody.
    Omidfar K; Amjad Zanjani FS; Hagh AG; Azizi MD; Rasouli SJ; Kashanian S
    Mol Biol Rep; 2013 Dec; 40(12):6737-45. PubMed ID: 24052234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural Basis of Epitope Recognition by Heavy-Chain Camelid Antibodies.
    Zavrtanik U; Lukan J; Loris R; Lah J; Hadži S
    J Mol Biol; 2018 Oct; 430(21):4369-4386. PubMed ID: 30205092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation.
    Talavera A; Friemann R; Gómez-Puerta S; Martinez-Fleites C; Garrido G; Rabasa A; López-Requena A; Pupo A; Johansen RF; Sánchez O; Krengel U; Moreno E
    Cancer Res; 2009 Jul; 69(14):5851-9. PubMed ID: 19584289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.